Follow-up of high-risk patients with differentiated thyroid cancer without persistent disease after initial therapy;Seguimento de pacientes de alto risco com carcinoma diferenciado de tireóide sem doença persistente após a terapia inicial

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 5, 2006, Pages 909-913

  Do Rosário, Pedro Weslley S ^a,c   Borges, Michelle A Ribeiro ^a   Alves, Maria Flávia Gatti ^a   Purisch, Saulo ^a   Padrão, Eduardo Lanza ^b   Rezende, Leonardo Lamego ^b   Barroso, Álvaro Luís ^b  

^a Servico de Endocrinologia   (Brazil)

^b Medicina Nuclear   (Brazil)

^c Centro de Estudos e Pesquisa   (Brazil)

Author keywords

Follow up; High risk; Thyroid cancer

Indexed keywords

RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; THYROGLOBULIN; THYROXINE;

ADENOCARCINOMA; ARTICLE; BLOOD; CATHETER ABLATION; EVALUATION; FEMALE; FOLLOW UP; HUMAN; IMMUNORADIOMETRIC ASSAY; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PAPILLARY CARCINOMA; PATIENT CARE; THYROID TUMOR; THYROIDECTOMY; TREATMENT OUTCOME; TUMOR RECURRENCE; WHOLE BODY IMAGING;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; CATHETER ABLATION; CONTINUITY OF PATIENT CARE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNORADIOMETRIC ASSAY; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOPHARMACEUTICALS; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROXINE; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 33845777436     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302006000500012     Document Type: Article

References (19)

1. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105-12.
2. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid carcinoma? J Clin Endocrinol Metab 2000;85:175-8.
3. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002;87:1499-501.
4. Rosario PW, Borges MA, Fagundes TA, Franco AC, Purisch S. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound? Clin Endocrinol 2005;62:121-5.
5. Robbins RJ, Tutle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:619-25.
6. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002;87:3242-7.
7. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, et al. Recombinant human thyrotropinstimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88:3668-73.
8. Mazzaferri EL. 1999 NCCN thyroid carcinoma practice guidelines. Oncology 1999;13(suppl. 11A):391-442. Available at: 〈http://www.nccn.org〉.
9. Rosario PW, de Faria S, Bicalho L, Alves MF, Borges MA, Purisch S, et al. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 2005;24:1385-9.
10. 131I activities versus untreated patients. J Clin Endocrinol Metab 2001;86:4092-7.
11. Coburn M, Teates D, Wanebo HJ. Recurrent thyroid cancer. Role of surgery versus radioactive iodine (131I). Ann Surg 1994;219:587-93; discussion 593-5.
12. 131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? Clin Nucl Med 2004;29:795-8.
13. Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 2005;90:5723-9.
14. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306.
15. Rosario PW, Barroso AL, Rezende L, Padrão EL, Maia FF, Fagundes TA, et al. 5 mCi pretreatment scanning does not cause stunning when the ablative dose is administered within 72 hours. Arq Bras Endocrinol Metab 2005;49:420-4.
16. 131I on postsurgical thyroid remnants. J Nucl Med 2000;41:2038-42.
17. Rosario P, Borges M, Reis J, Alves MA. Effect of suppressive therapy with levothyroxine on the reduction of serum thyroglobulin after total thyroidectomy. Thyroid 2006;16:199-200.
18. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 2004;89:3402-7.
19. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.